Autonomic regulation therapy to enhance myocardial function in heart failure patients: the ANTHEM-HFpEF study. by DiCarlo, Lorenzo A et al.
UCLA
UCLA Previously Published Works
Title
Autonomic regulation therapy to enhance myocardial function in heart failure patients: 
the ANTHEM-HFpEF study.
Permalink
https://escholarship.org/uc/item/20b1t6d2
Journal
ESC heart failure, 5(1)
ISSN
2055-5822
Authors
DiCarlo, Lorenzo A
Libbus, Imad
Kumar, H Uday
et al.
Publication Date
2018-02-01
DOI
10.1002/ehf2.12241
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Autonomic regulation therapy to enhance myocardial
function in heart failure patients: the ANTHEM-HFpEF
study
Lorenzo A. DiCarlo1, Imad Libbus1, H. Uday Kumar2, Sanjay Mittal3, Rajendra K. Premchand4, Badri Amurthur1,
Bruce H. KenKnight1, Jeffrey L. Ardell5 and Inder S. Anand6*
1LivaNova PLC, London, UK; 2Yashoda Hospital, Secunderabad, India; 3Medanta—The Medicity, New Delhi, India; 4Krishna Institute of Medical Science, Secunderabad, India;
5University of California—Los Angeles, Los Angeles, CA, USA; 6Minneapolis VA Health Care System, University of Minnesota, Cardiology 111 C, One Veterans Drive,
Minneapolis, MN 55417, USA
Abstract
Background Approximately half of the patients presenting with new-onset heart failure (HF) have HF with preserved left
ventricular ejection fraction (HFpEF) and HF with mid-range left ventricular ejection fraction (HFmrEF). These patients have
neurohormonal activation like that of HF with reduced ejection fraction; however, beta-blockers and angiotensin-converting
enzyme inhibitors have not been shown to improve their outcomes, and current treatment for these patients is symptom
based and empiric. Sympathoinhibition using parasympathetic stimulation has been shown to improve central and peripheral
aspects of the cardiac nervous system, reflex control, induce myocyte cardioprotection, and can lead to regression of left ven-
tricular hypertrophy. Beneficial effects of autonomic regulation therapy (ART) using vagus nerve stimulation (VNS) have also
been observed in several animal models of HFpEF, suggesting a potential role for ART in patients with this disease.
Methods The Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Patients with Heart Failure and
Preserved Ejection Fraction (ANTHEM-HFpEF) study is designed to evaluate the feasibility, tolerability, and safety of ART using
right cervical VNS in patients with chronic, stable HFpEF and HFmrEF. Patients with symptomatic HF and HFpEF or HFmrEF
fulfilling the enrolment criteria will receive chronic ART with a subcutaneous VNS system attached to the right cervical vagus
nerve. Safety parameters will be continuously monitored, and cardiac function and HF symptoms will be assessed every
3 months during a post-titration follow-up period of at least 12 months.
Conclusions The ANTHEM-HFpEF study is likely to provide valuable information intended to expand our understanding of
the potential role of ART in patients with chronic symptomatic HFpEF and HFmrEF.
Keywords Autonomic balance; Heart failure; Preserved ejection fraction; Neuromodulation; Autonomic regulation therapy; Vagus
nerve stimulation
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Introduction
Approximately 50% of patients with heart failure (HF) have
preserved and mid-range left ventricular ejection fraction
(LVEF; ≥40%) with or without features of diastolic dysfunc-
tion.1 Hallmarks of diastolic dysfunction include left atrial
enlargement, elevated E/e0 ratio [the peak mitral velocity
of early filling (E) divided by early diastolic mitral annular
velocity (e0)], left ventricular hypertrophy, and elevated
circulating natriuretic peptides.1–3 The pathological changes
in the left ventricle (LV) include myocyte hypertrophy,
apoptosis, necrosis, and excessive interstitial collagen
deposition in the myocardium.4 As in patients with HF
with reduced ejection fraction (HFrEF), patients with HF
with preserved LVEF (HFpEF; LVEF ≥ 50%) and HF with
mid-range LVEF [HFmrEF; ejection fraction (EF) = 40–49%]
also have significant neurohormonal activation with poor
outcomes.5–7
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While there have been significant therapeutic advances for
patients with HFrEF through the use of neurohormonal
antagonists and device-based therapies such as cardiac
resynchronization, definitive treatment interventions for
patients with HFpEF and HFmrEF have been not been identi-
fied.8 In particular, beta-blockers and angiotensin-converting
enzyme inhibitors have not been shown to improve out-
comes. Only two agents, angiotensin receptor blockers
(ARBs) and aldosterone receptor antagonists (ARAs), have
been shown to reduce hospitalizations in selected HFpEF
patients.9,10 Recent guidelines list both these agents as Class
IIb therapies, and current treatment of HFpEF and HFmrEF
remains symptom based and empirical.11 In addition to ARBs
and ARAs, pharmacological management typically consists of
diuretics for the amelioration of symptomatic volume
overload, rate control for patients with atrial fibrillation,
and management of co-morbidities such as hypertension.12,13
There is considerable rationale for testing the use of auto-
nomic modulation with vagus nerve stimulation (VNS) in pa-
tients with HFpEF and HFmrEF. Autonomic dysregulation is
an important component of HFpEF and HFmrEF, and patients
with HFpEF and HFmrEF show a similar pattern of neurohor-
monal activation to those with HFrEF.8 Vagus nerve stimula-
tion increases parasympathetic activity, reduces sympathetic
tone, and stabilizes the neural network in the autonomic ner-
vous system regulating cardiovascular function.14 Increased
parasympathetic activity results in increased muscarinic
receptor activation and decreases excess adrenergic receptor
activation.15 Muscarinic receptor activation at the level of the
cardiac myocyte reduces oxidative stress, increases contrac-
tile function, improves calcium signalling function in the heart,
and normalizes gene expression.15,16 At the same time, cholin-
ergic trans-differentiation of sympathetic neurons takes place,
providing a protective role against sympathetically mediated
pathogenesis.17 In canine and guinea pig models of
hypertension-mediated HF, chronic VNS was shown to miti-
gate hypertrophy and reverse multiple adverse changes in
autonomic control of the heart, including myocyte size and
LV mass, findings that are particularly relevant to HFpEF.18,19
Although VNS has never been clinically evaluated in HFpEF
and HFmrEF patients, several clinical studies have been
conducted in HFrEF patients. The Neural Cardiac Therapy
for Heart Failure (NECTAR-HF) study was a randomized
controlled study that evaluated the effect of right cervical
VNS in 96 patients with HFrEF.20 This study failed to meet
its primary endpoint, 6-month improvement in LV end
systolic diameter, although quality of life and New York Heart
Association (NYHA) class were both significantly improved. As
the investigators themselves note, the failure of the NECTAR-
HF study was likely due to the high frequency of stimulation
of the vagus nerve (20 Hz), which elicited patient intolerance
and prevented titration to a therapeutic dose. The Increase of
Vagal Tone in Heart Failure (INOVATE-HF) study, a pivotal trial
in 707 patients, was stopped early for futility. The study failed
to meet its primary endpoint, reduction in death or HF
events, despite significant improvements in several second-
ary endpoints (NYHA class, quality of life, and 6 min walk
distance).21 Post hoc analysis of the INOVATE-HF study
demonstrated that adequate stimulation levels were not
reached across all patients and that poor response to VNS
was seen in 30% of patients with cardiac resynchronization
therapy devices.
Autonomic Neural Regulation Therapy to Enhance
Myocardial Function in Heart Failure (ANTHEM-HF) studied
60 patients with HFrEF and demonstrated that VNS is safe, is
feasible, and results in improvements in cardiac function and
HF symptoms.22,23 In that study, stimulation was delivered
at a moderate intensity (2.0 ± 0.6 mA) and a frequency of
5–10 Hz (near the natural frequency of discharge of vagal
fibres during physiological reflex activation24,25). The device
used in the ANTHEM-HF study (VITARIA, LivaNova PLC,
London, UK) received Conformité Europeénne Mark approval
in 2015 for the treatment of HFrEF.26
The Autonomic Neural Regulation Therapy to Enhance
Myocardial Function in Patients with Heart Failure and Pre-
served Ejection Fraction (ANTHEM-HFpEF) study is designed
to evaluate the feasibility, tolerability, and safety of auto-
nomic regulation therapy (ART) using right cervical VNS in pa-
tients with chronic symptomatic HFpEF and HFmrEF.
Methods
Study design
The ANTHEM-HFpEF is an open-label, multicentre, single-arm
study. It is anticipated that approximately eight study sites
will enrol approximately 50 study subjects. Each study subject
will participate in the study for at least 15 months.
Device implantation and vagus nerve stimulation
titration
The VNS Therapy System (LivaNova PLC) will be used to deliver
ART for this study. The functionally equivalent VITARIA™
system received Conformité Europeénne Mark approval in
2015 for the treatment of HFrEF patients who have symptom-
atic moderate to severe HF (NYHA Class II/III) with LV
dysfunction (LVEF ≤ 40%), despite stable, optimal HF drug
therapy. The system has been described in detail previously.27
The ART system will be implanted subcutaneously, follow-
ing the approved implantation procedure for patients with
HF. The lead, including bipolar electrodes (anode cephalad
to cathode), will be placed on the right cervical vagus nerve
through a transverse incision in the neck halfway between
the clavicle and the mastoid process. The lead body will be
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tunnelled subcutaneously from the neck incision site to the
pulse generator in an ipsilateral, subclavicular chest pocket.
After a 2-week post-implantation recovery period and a
10-week stimulation titration period, continuous cyclic
stimulation will be delivered for at least 12 months.
Study objectives
The main objectives of the ANTHEM-HFpEF are to evaluate
the feasibility, tolerability, and safety of ART via VNS for the
treatment of patients with HFpEF and HFmrEF. The study will
also seek to identify signals of clinical improvement. Feasibil-
ity is defined as the percentage of study subjects who are
successfully implanted with the lead and pulse generator,
based upon implant attempt. Tolerability is defined as the
percentage of study subjects who continue therapy through-
out the follow-up period that begins after post-implantation
titration of VNS is complete. Safety is defined as the inci-
dence of procedure-related and device-related adverse
events.
The pilot study will also seek to identify signals of
cardiovascular and functional improvement in patients with
HFpEF and HFmrEF. The following efficacy measurements
will be made at baseline and at each follow-up visit: echo-
cardiographic assessment of cardiac structure and function
including left atrial volume index, LV mass, and Doppler in-
dices of LV diastolic function; measurements of functional
status such as NYHA class, quality of life using the Minne-
sota Living with Heart Failure Questionnaire, 6 min walk
distance, mean heart rate, and heart rate variability during
24 h Holter electrocardiography; and plasma biomarkers
including N-terminal pro-BNP and high-sensitivity C-reactive
protein.
Study population
Male and female patients 18 years of age or older, with NYHA
Class II or III HF symptoms, on stable guideline-directed
pharmacologic therapy including a loop diuretic for at least
1month, with controlled systolic blood pressure (<140mmHg)
or systolic blood pressure between 140 and 160 mmHg, and
receiving three or more blood pressure medications will be
eligible for enrolment. Other key inclusion criteria include
LVEF ≥ 40%, plasma N-terminal pro-BNP ≥ 220 pg/mL, ratio
of mitral inflow velocity to early diastolic velocity of the mitral
annulus (E/e0) > 15, or E/e0 > 8 and left atrial enlargement
(left atrial volume index ≥ 29 mL/m2) (Figure 1). Subjects must
be physically capable and willing to perform repeated 6 min
walk tests and achieve a baseline distance of between 150
and 425 m that is limited by symptoms due to HF.
Exclusion criteria include HF due to congenital heart
disease, hypertrophic or restrictive cardiomyopathy, a recent
HF hospitalization or intravenous HF therapy in the past
30 days, therapeutic cardiovascular intervention or surgery
within the past 2 months or planned within the next 6 months,
participation in an investigational drug or device trial currently
or in the past 3 months, or suffering from a medical or surgical
condition that could reduce life expectancy or present an
unacceptable risk from ART system implantation or VNS.
Study treatment
Subjects who fulfil all of the inclusion and exclusion criteria
and provide written informed consent will receive thoracic
subcutaneous ART therapy system implantation for right
cervical VNS. After a 2-week post-implant recovery period,
Figure 1 Key inclusion criteria for determining HFpEF patients eligible for
enrolment in the Autonomic Neural Regulation Therapy to Enhance
Myocardial Function in Patients with HFpEF study. HFpEF, heart failure
with preserved ejection fraction; LVEF, left ventricular ejection fraction;
NT, N-terminal.
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the device will be activated and VNS will be initiated at a cur-
rent output of 0.25 mA, pulse frequency of 5 Hz, pulse width
of 130 μs, and a duty cycle of 17.5% (14 s on/66 s off). The
titration period will have a duration of approximately
10 weeks. During the titration period, stimulation parameters
will be adjusted during weekly titration sessions in a
prescribed stepwise fashion under continuous electrocardiog-
raphy monitoring and recording to a maximum current
output of 3.0 mA, pulse frequency of 5 Hz, pulse width of
250 μs, and a duty cycle of 17.5% (14 s on/66 s off), limited
by VNS-related side effects such as activation of the expira-
tory reflex (mild cough), intolerable stimulation sensation,
or acute heart rate reduction (>4 b.p.m.) during VNS active
phase. Once the titration period is complete, VNS therapy will
continue for at least 12 months.
Subjects will be instructed regarding potential adverse
device-related effects and will be provided a magnet to
inhibit pulse generator stimulation in the event of any
intolerable device-related effects. Should subjects perform
this intervention, they will be instructed to contact the site
investigator, who will assess whether an adverse device-
related event has occurred and whether the programmed
settings should be changed.
Study analysis
All echocardiographic recordings and blood samples will be
sent to a designated core laboratory facility for analysis. Data
will be batched for analysis, and analysis will incorporate
blinding to the study subject and the temporal order of the
data being analysed. All adverse events will be reviewed by
an independent clinical events committee that will adjudicate
adverse event severity and whether or not an adverse event
is device related. An independent data and safety monitoring
committee will oversee the study, and the study will be
analysed using the following statistical analysis plan.
Because the focus of the study is on feasibility and safety,
the sample size for this study was not statistically derived.
Data from all investigational sites will be pooled for analysis.
Standard statistical methods will be employed to analyse all
data. Continuous variables will be summarized using the num-
ber of observations, mean, median, standard deviation, and
minimum and maximum values. Variables that are not nor-
mally distributed will be log transformed. Categorical variables
will be summarized using the number of observations and
percentages. Statistical significance testing will be performed
at the 0.05 level. All tests of hypotheses will be two-tailed.
Study risks and mitigations
The most commonly reported side effects of VNS include mild
cough, voice alteration, paraesthesia, nausea, dyspepsia, and
dyspnoea. Vagus nerve stimulation is also known to affect the
sinoatrial and atrioventricular nodes. The protocol requires
stimulation titration below the threshold of significant
cardiac (heart rate and atrioventricular conduction) effects;
however, there is a risk that stimulation could cause mild
acute increase or decrease in heart rate, depending on the
VNS parameters that are utilized.28
The study is designed to mitigate each of these risks.
Subjects will be monitored for symptomatic tolerability and
any significant increase or decrease in heart rate while the
intensity of VNS is being titrated in a clinical setting. Subjects
will be observed weekly during therapy titration, and cardiac
rhythm will be assessed. If atrial fibrillation develops and is
considered to be related to VNS, the clinical investigators
may temporarily or permanently discontinue VNS. The
subjects will also be observed closely during the first 12 weeks
of the study, and if worsening HF is observed, investigators
may consider discontinuing VNS.
Discussion
Approximately half of the patients presenting with new-onset
HF have HFrEF, and half have HFpEF and HFmrEF. The LV of
patients with HFrEF is generally enlarged and may appear
thin walled on echocardiography with an EF ≤ 40%. In
contrast, patients with HFpEF and HFmrEF typically have
LVs that are generally normal or thick walled, with LVEF-
40%, and LV volume that is reduced. The 2016 updates of
guidelines for the treatment of HF introduced a new category
of HF with mid-range LVEF to describe patients with HF and
LVEF ranging from 40% to 49% (HFmrEF), reserving HFpEF
to describe patients with HF and LVEF ≥ 50%. The ANTHEM-
HFpEF study was designed and launched before these
guideline revisions were introduced and includes both HFpEF
and HFmrEF in the study population. The characteristics and
outcomes of patients with HFmrEF currently appear to be
similar to those with HFpEF, and there are currently limited
evidence-based treatments for patients with an LVEF of
40% or greater.11–13
Despite differences in the hearts of patients with HFrEF,
HFpEF, and HFmrEF, the signs, symptoms, and other clinical
manifestations are very similar in all three conditions. The
pathophysiological mechanisms of salt and water retention
are also very similar. In both conditions, there is an auto-
nomic imbalance with increase in sympathetic and renin–an-
giotensin–aldosterone system activity and withdrawal of
parasympathetic efferent activity.29 However, unlike the
dramatic improvement in outcomes seen with the use
of blockers of the sympathetic and renin–angiotensin–
aldosterone system in patients with HFrEF, beta-blockers
and angiotensin-converting enzyme inhibitors have not been
demonstrated in patients with HFpEF or HFmrEF, and ARBs
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and ARAs have only a modest effect on HF hospitalization.
Whether enhancing parasympathetic tone by VNS may be
beneficial in patients with HFpEF and HFmrEF has not been
examined. However, existing pre-clinical and clinical evidence
is available, demonstrating that sympathoinhibition using
parasympathetic interventions leads to improvements in
central and peripheral neural network functions, barorecep-
tor reflexes, myocyte energetics, and regression of LV
hypertrophy.15,17,30,31
Studies in a guinea pig model of pressure-overload LV
hypertrophy have shown improvement in echocardio-
graphic features of LVH and LV filling, suggesting a
potential role of ART in HFpEF and HFmrEF.18 In a canine
model of HFpEF using bilateral non-restrictive renal
wrapping, which induced increased blood pressure and
increased LV mass, ART induced a significant regression of
LV mass and enhanced inotropic and lusitropic response
to direct stellate stimulation, suggesting that ART improved
cardiovascular autonomic control.19 Early clinical studies of
ART have shown promising safety and efficacy trends when
VNS is properly titrated to a defined target in appropriately
selected patients with HFrEF,22,23,32 and there are two ART
systems currently approved for clinical use for HFrEF in
Europe.26,33
Based upon these considerations, the ANTHEM-HFpEF
study has been designed to examine the feasibility,
tolerability, safety, and potential benefits of ART via VNS
using the LivaNova VNS Therapy System in patients with
EF ≥ 40%.
Summary
By investigating the feasibility, tolerability, and potential
benefits of ART in patients with HFpEF and HFmrEF and
complementing the previously published ANTHEM-HF study
in patients with HFrEF, the ANTHEM-HFpEF study will serve
to expand our understanding of the role of ART in patients
with chronic symptomatic HF.
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